{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:53:42Z","timestamp":1783338822439,"version":"3.54.6"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Key Clinical Specialty for Laboratory Medicine - Excellent Project","award":["ZK201000"],"award-info":[{"award-number":["ZK201000"]}]},{"name":"Beijing Key Clinical Specialty for Laboratory Medicine - Excellent Project","award":["ZK201000"],"award-info":[{"award-number":["ZK201000"]}]},{"name":"Beijing Key Clinical Specialty for Laboratory Medicine - Excellent Project","award":["ZK201000"],"award-info":[{"award-number":["ZK201000"]}]},{"name":"Beijing Key Clinical Specialty for Laboratory Medicine - Excellent Project","award":["ZK201000"],"award-info":[{"award-number":["ZK201000"]}]},{"name":"Beijing Key Clinical Specialty for Laboratory Medicine - Excellent Project","award":["ZK201000"],"award-info":[{"award-number":["ZK201000"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072318"],"award-info":[{"award-number":["82072318"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2301002, 2021YFC2301000"],"award-info":[{"award-number":["2021YFC2301002, 2021YFC2301000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Data on antibiotic resistance is essential to adapt treatment strategies against the rapidly changing reality of antimicrobial resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To study the in vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and Gram-negative bacteria collected from China in the year 2018.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 2301 clinical isolates were collected from 17 medical center laboratories in China, which participated in the ATLAS program in 2018. Antimicrobial susceptibilities were determined by the broth microdilution method at a central laboratory. Clinical and Laboratory Standards Institute (CLSI) breakpoints were used to interpret the results except for tigecycline, for which the US Food and Drug Administration (FDA) breakpoint were used.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The susceptibility rates of methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA), penicillin-resistant <jats:italic>Streptococcus pneumoniae<\/jats:italic> (PRSP), and \u03b2-hemolytic streptococcus to ceftaroline were 83.9%, 100%, and 100%, respectively. <jats:italic>Escherichia coli<\/jats:italic>, imipenem-susceptible (IMP-S) <jats:italic>Escherichia coli<\/jats:italic>, <jats:italic>Klebsiella pneumoniae<\/jats:italic>, <jats:italic>Enterobacter cloacae<\/jats:italic>, IMP-S <jats:italic>Enterobacter cloacae<\/jats:italic>, <jats:italic>Proteus mirabilis<\/jats:italic>, <jats:italic>Morganella morganii<\/jats:italic>, <jats:italic>Serratia marcescens<\/jats:italic> and <jats:italic>Pseudomonas aeruginosa<\/jats:italic> had high susceptibility rates to ceftazidime-avibactam (95.8%, 100%, 97.7%, 94.5%, 100%, 90.2%, 96.0%, 97.5% and 90.7%, respectively). However, imipenem-resistant <jats:italic>Escherichia coli<\/jats:italic> and imipenem-resistant <jats:italic>Pseudomonas aeruginosa<\/jats:italic> demonstrated low susceptibility to ceftazidime-avibactam (33.3% and 75.8%, respectively). Against MRSA, methicillin-susceptible <jats:italic>Staphylococcus aureus<\/jats:italic> (MSSA), <jats:italic>S. pneumoniae<\/jats:italic> and \u03b2-hemolytic streptococci, the susceptibility rates of tigecycline were 93.5%, 99.2%, 100% and 100%, respectively. Levofloxacin also showed high in vitro activity against <jats:italic>S. pneumoniae<\/jats:italic> and \u03b2-hemolytic streptococci with a susceptibility rate of 100% and 98.4%. The susceptibility rate of <jats:italic>E. faecalis<\/jats:italic> to ampicillin was 100%. Among Gram-negative isolates, tigecycline and colistin showed good activity against <jats:italic>E. coli<\/jats:italic>, <jats:italic>K. pneumoniae<\/jats:italic>, imipenem-resistant <jats:italic>E. cloacae<\/jats:italic>, <jats:italic>C. freundii<\/jats:italic> and <jats:italic>A. baumannii<\/jats:italic> (susceptibility rates and intermediate susceptibility rates of 99.3% and 96.8%, 95.4% and 94.5%, 100% and 87.5%, 96.4% and 89.3%, MIC<jats:sub>90<\/jats:sub> of 2\u00a0mg\/L and 97.4%, respectively). <jats:italic>E. coli<\/jats:italic> and <jats:italic>E. cloacae<\/jats:italic> had high susceptibility rates to imipenem and meropenem (93.0% and 92.8%, 89.8% and 92.1%, respectively). <jats:italic>M. morganii<\/jats:italic> and <jats:italic>P. mirabilis<\/jats:italic> demonstrated meropenem and piperacillin-tazobactam susceptibility rates of 96.0% and 94.0%, 94.1% and 92.2%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Ceftaroline showed good activity among tested antimicrobial agents against Gram-positive species, while ceftazidime-avibactam had good activity against <jats:italic>Escherichia coli<\/jats:italic>, <jats:italic>Klebsiella pneumoniae<\/jats:italic>, <jats:italic>Enterobacter cloacae<\/jats:italic>, <jats:italic>Proteus mirabilis<\/jats:italic>, <jats:italic>Morganella morganii<\/jats:italic>, <jats:italic>Serratia marcescens<\/jats:italic> and <jats:italic>Pseudomonas aeruginosa<\/jats:italic> excluding carbapenem-resistant isolates.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12866-022-02644-5","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T11:02:44Z","timestamp":1664622164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program"],"prefix":"10.1186","volume":"22","author":[{"given":"Peiyao","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,1]]},"reference":[{"key":"2644_CR1","unstructured":"World Health Organization. Antimicrobial resistance: global report on surveillance 2014.https:\/\/www.who.int\/drugresistance\/documents\/surveillancereport\/en\/. Accessed June 3, 2020. Geneva: World Health Organization; 2014."},{"key":"2644_CR2","unstructured":"Centers for Diseases Control and Prevention. Antibiotic Resistance Threats in the United States, 2013.https:\/\/www-cdc-gov.acces.bibl.ulaval.ca\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf#page=49. Accessed June 3, 2020. Atlanta: Centers for Diseases Control and Prevention; 2013."},{"key":"2644_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.micpath.2016.02.009","volume":"95","author":"B Khameneh","year":"2016","unstructured":"Khameneh B, Diab R, Ghazvini K, Fazly Bazzaz BS. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microb Pathog. 2016;95:32\u201342.","journal-title":"Microb Pathog"},{"issue":"23","key":"2644_CR4","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.1002\/anie.201506818","volume":"55","author":"MF Chellat","year":"2016","unstructured":"Chellat MF, Raguz L, Riedl R. Targeting Antibiotic Resistance. Angew Chem. 2016;55(23):6600\u201326.","journal-title":"Angew Chem"},{"key":"2644_CR5","doi-asserted-by":"crossref","unstructured":"Qu J, Huang Y, Lv X: Crisis of Antimicrobial Resistance in China: Now and the Future. Frontiers in microbiology 2019, 10:2240.","DOI":"10.3389\/fmicb.2019.02240"},{"key":"2644_CR6","doi-asserted-by":"crossref","unstructured":"Duplessis C, Crum-Cianflone NF. Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA). Clinical medicine reviews in therapeutics 2011, 3.","DOI":"10.4137\/CMRT.S1637"},{"key":"2644_CR7","unstructured":"Bui T, Preuss CV: Cephalosporins. In: StatPearls. Treasure Island (FL); 2021."},{"issue":"1","key":"2644_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11096-016-0417-z","volume":"39","author":"MS El Hajj","year":"2017","unstructured":"El Hajj MS, Turgeon RD, Wilby KJ. Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review. Int J Clin Pharm. 2017;39(1):26\u201332.","journal-title":"Int J Clin Pharm"},{"issue":"9","key":"2644_CR9","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S1473-3099(15)00139-5","volume":"15","author":"SA Pawluk","year":"2015","unstructured":"Pawluk SA, Wilby KJ. Ceftaroline fosamil for community-acquired pneumonia. Lancet Infect Dis. 2015;15(9):999.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2644_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40121-014-0036-8","volume":"3","author":"JJ Carreno","year":"2014","unstructured":"Carreno JJ, Lodise TP. Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE. Infect Dis therapy. 2014;3(2):123\u201332.","journal-title":"Infect Dis therapy"},{"key":"2644_CR11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/TCRM.S75412","volume":"11","author":"MA Mpenge","year":"2015","unstructured":"Mpenge MA, MacGowan AP. Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia. Ther Clin Risk Manag. 2015;11:565\u201379.","journal-title":"Ther Clin Risk Manag"},{"key":"2644_CR12","unstructured":"Khanna NR, Gerriets V: Beta Lactamase Inhibitors. In: StatPearls. Treasure Island (FL); 2021."},{"issue":"6","key":"2644_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections. Drugs. 2018;78(6):675\u201392.","journal-title":"Drugs"},{"key":"2644_CR14","unstructured":"National Institute for Health and Care Excellence. Antimicrobial prescribing: Ceftazidime\/avibactam. Evidence summary [ES16]. London: National Institute for Health and Care Excellence (NICE); 2017."},{"issue":"4","key":"2644_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ijantimicag.2014.12.014","volume":"45","author":"H Zhang","year":"2015","unstructured":"Zhang H, Xiao M, Kong F, O\u2019Sullivan MVN, Mao L-L, Zhao H-R, Zhao Y, Wang H, Xu Y-C. A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology. Int J Antimicrob Agents. 2015;45(4):347\u201350.","journal-title":"Int J Antimicrob Agents"},{"key":"2644_CR16","doi-asserted-by":"crossref","unstructured":"Wang X, Zhang F, Zhao C, Wang Z, Nichols WW, Testa R, Li H, Chen H, He W, Wang Q, et al: In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrobial agents and chemotherapy 2014, 58(3):1774\u20131778.","DOI":"10.1128\/AAC.02123-13"},{"issue":"suppl_2","key":"2644_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/cid\/ciy659","volume":"67","author":"M Zhou","year":"2018","unstructured":"Zhou M, Chen J, Liu Y, Hu Y, Liu Y, Lu J, Zhang S, Yu Y, Huang X, Yang Q, et al. In Vitro Activities of Ceftaroline\/Avibactam, Ceftazidime\/Avibactam, and Other Comparators Against Pathogens From Various Complicated Infections in China. Clin Infect diseases: official publication Infect Dis Soc Am. 2018;67(suppl_2):206\u201316.","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"key":"2644_CR18","doi-asserted-by":"crossref","unstructured":"Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 2019, 63(4).","DOI":"10.1128\/AAC.02431-18"},{"issue":"6","key":"2644_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1089\/sur.2013.172","volume":"15","author":"CE Edmiston Jr","year":"2014","unstructured":"Edmiston CE Jr, Krepel CJ, Leaper D, Ledeboer NA, Mackey TL, Graham MB, Lee C, Rossi PJ, Brown KR, Lewis BD, et al. Antimicrobial activity of ceftaroline and other anti-infective agents against microbial pathogens recovered from the surgical intensive care patient population: a prevalence analysis. Surg Infect. 2014;15(6):745\u201351.","journal-title":"Surg Infect"},{"issue":"1","key":"2644_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13756-020-00829-z","volume":"9","author":"H Zhang","year":"2020","unstructured":"Zhang H, Xu Y, Jia P, Zhu Y, Zhang G, Zhang J, Duan S, Kang W, Wang T, Jing R, et al. Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012\u20132016). Antimicrob Resist Infect control. 2020;9(1):166.","journal-title":"Antimicrob Resist Infect control"},{"issue":"6","key":"2644_CR21","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ijantimicag.2014.12.033","volume":"45","author":"R Testa","year":"2015","unstructured":"Testa R, Canton R, Giani T, Morosini MI, Nichols WW, Seifert H, Stefanik D, Rossolini GM, Nordmann P. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates. Int J Antimicrob Agents. 2015;45(6):641\u20136.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"2644_CR22","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1128\/AAC.02429-13","volume":"58","author":"HS Sader","year":"2014","unstructured":"Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother. 2014;58(3):1684\u201392.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2644_CR23","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/cid\/cis270","volume":"54","author":"P Prasad","year":"2012","unstructured":"Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54(12):1699\u2013709.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2644_CR24","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1128\/AAC.00387-11","volume":"55","author":"MJ Satlin","year":"2011","unstructured":"Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, Jenkins SG, Calfee DP. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother. 2011;55(12):5893\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2644_CR25","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1128\/AAC.06064-11","volume":"56","author":"P Levasseur","year":"2012","unstructured":"Levasseur P, Girard AM, Claudon M, Goossens H, Black MT, Coleman K, Miossec C. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2012;56(3):1606\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2644_CR26","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1128\/AAC.01696-10","volume":"55","author":"A Walkty","year":"2011","unstructured":"Walkty A, DeCorby M, Lagace-Wiens PR, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother. 2011;55(6):2992\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"2644_CR27","doi-asserted-by":"crossref","unstructured":"Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, Zhang XJ, Zhang CX, Ji P, Xie Y, et al: Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005\u20132014. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2016, 22 Suppl 1:S9-14.","DOI":"10.1016\/j.cmi.2016.01.001"},{"key":"2644_CR28","doi-asserted-by":"crossref","unstructured":"Yin S, Chen P, You B, Zhang Y, Jiang B, Huang G, Yang Z, Chen Y, Chen J, Yuan Z, et al: Molecular Typing and Carbapenem Resistance Mechanisms of Pseudomonas aeruginosa Isolated From a Chinese Burn Center From 2011 to 2016. Frontiers in microbiology 2018, 9:1135.","DOI":"10.3389\/fmicb.2018.01135"},{"issue":"2","key":"2644_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1473-3099(22)00009-3","volume":"22","author":"C Liu","year":"2022","unstructured":"Liu C, Dong N, Chan EWC, Chen S, Zhang R. Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in China, 2016-20. Lancet Infect Dis. 2022;22(2):167\u20138.","journal-title":"Lancet Infect Dis"},{"key":"2644_CR30","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B, Xie L, Yang C, Ma X, Li H, et al: Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network. Antimicrobial agents and chemotherapy 2018, 62(2).","DOI":"10.1128\/AAC.01882-17"},{"key":"2644_CR31","doi-asserted-by":"crossref","unstructured":"Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF: In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrobial agents and chemotherapy 2018, 62(7).","DOI":"10.1128\/AAC.02569-17"},{"issue":"Suppl 3","key":"2644_CR32","first-page":"iii69","volume":"66","author":"RN Jones","year":"2011","unstructured":"Jones RN, Farrell DJ, Mendes RE, Sader HS. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother. 2011;66(Suppl 3):iii69\u201380.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2644_CR33","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1128\/AAC.02794-15","volume":"60","author":"HS Sader","year":"2016","unstructured":"Sader HS, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014. Antimicrob Agents Chemother. 2016;60(4):2558\u201363.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2644_CR34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4037\/aacnacc2016612","volume":"27","author":"KA Connor","year":"2016","unstructured":"Connor KA. Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam. AACN Adv Crit Care. 2016;27(4):353\u20137.","journal-title":"AACN Adv Crit Care"},{"issue":"10","key":"2644_CR35","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1093\/jac\/dky267","volume":"73","author":"KM Kazmierczak","year":"2018","unstructured":"Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime\/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15. J Antimicrob Chemother. 2018;73(10):2777\u201381.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2644_CR36","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1128\/AAC.04614-14","volume":"59","author":"HS Sader","year":"2015","unstructured":"Sader HS, Flamm RK, Streit JM, Farrell DJ, Jones RN. Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program. Antimicrob Agents Chemother. 2015;59(4):2458\u201361.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2644_CR37","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.diagmicrobio.2016.07.012","volume":"86","author":"JA Karlowsky","year":"2016","unstructured":"Karlowsky JA, Biedenbach DJ, Bouchillon SK, Hackel M, Iaconis JP, Sahm DF. In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012\u20132014. Diagn Microbiol Infect Dis. 2016;86(2):194\u20139.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2644_CR38","doi-asserted-by":"crossref","unstructured":"Bae IG, Stone GG. Activity of ceftaroline against pathogens associated with community-acquired pneumonia collected as part of the AWARE surveillance program, 2015\u20132016. Diagn Microbiol Infect Dis 2019:114843.","DOI":"10.1016\/j.diagmicrobio.2019.05.015"},{"issue":"Suppl 3","key":"2644_CR39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/cid\/cis562","volume":"55","author":"RK Flamm","year":"2012","unstructured":"Flamm RK, Sader HS, Farrell DJ, Jones RN. Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program. Clin Infect Dis. 2012;55(Suppl 3):194\u2013205.","journal-title":"Clin Infect Dis"},{"key":"2644_CR40","doi-asserted-by":"publisher","first-page":"k462","DOI":"10.1136\/bmj.k462","volume":"360","author":"S Mayor","year":"2018","unstructured":"Mayor S. First WHO antimicrobial surveillance data reveal high levels of resistance globally. BMJ. 2018;360:k462.","journal-title":"BMJ"},{"key":"2644_CR41","unstructured":"World Health Organization. Global Antimicrobial Resistance Surveillance System (GLASS) report: early implementation. 2016-17. 2017. http:\/\/apps.who.int\/iris\/bitstream\/10665\/259744\/1\/9789241513449-eng.pdf?ua=1. Retrieved August 21, 2019. Geneva: World Health Organization; 2017."},{"key":"2644_CR42","unstructured":"Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing: 31thed. Document M100-S31. Wayne: Clinical and Laboratory Standards Institute; 2021."}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-022-02644-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-022-02644-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-022-02644-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T11:04:08Z","timestamp":1664622248000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-022-02644-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2644"],"URL":"https:\/\/doi.org\/10.1186\/s12866-022-02644-5","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]},"assertion":[{"value":"6 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol has been reviewed by the human research Ethics Committee of the Institutional Review Board (IRB) of the Peking Union Medical College Hospital (Ethics Approval Number: S-K467). This project did not involve any patient information, nor did it affect the normal diagnosis and treatment of patients. After consultation with the IRB, formal ethical approval was reviewed and waived, and written patient consent was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"234"}}